A third-generation IMiD for MM

Abstract

In this issue of Blood, Lacy et al report that pomalidomide overcomes refractoriness to prior therapy with lenalidomide and bortezomib, thus representing a new and valuable treatment option for patients who have exhausted major novel agent-based strategies for the management of multiple myeloma.